219635-89-9

Usage

Uses

Used in Pharmaceutical Industry:
1-(5-IODO-PYRIDIN-2-YL)-PIPERAZINE is used as a ligand for various receptors in the central nervous system, particularly for the development of antipsychotic and anti-anxiety medications. Its potential therapeutic effects are being studied, making it a valuable compound in the search for new treatments for mental health disorders.
Used in Organic Synthesis and Chemical Research:
Due to its unique structure and reactivity, 1-(5-IODO-PYRIDIN-2-YL)-PIPERAZINE may also have applications in organic synthesis and chemical research. Its properties can be leveraged to create new compounds and contribute to the advancement of chemical science.
It is important to handle 1-(5-IODO-PYRIDIN-2-YL)-PIPERAZINE with care, as iodine-containing substances can be hazardous and may require special handling and disposal protocols to ensure safety in the laboratory and pharmaceutical settings.

InChI:InChI=1/C9H12IN3/c10-8-1-2-9(12-7-8)13-5-3-11-4-6-13/h1-2,7,11H,3-6H2

Upstream product

• 110-85-0 piperazine 
• 69045-79-0 2-choro-5-iodopyridine 
• 73290-22-9 2-bromo-5-iodo-pyridine 
• 497915-42-1 4-(5-iodopyridin-2-yl)piperazine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 1029360-03-9 4-(5-iodo-2-pyridyl)piperazino-2-trifluoromethylphenylmethanone 
• 1170318-74-7 4-(5-iodopyridin-2-yl)-N-(4-sulfamoylphenyl)piperazine-1-carbothioamide 

Relevant academic research and scientific papers

ACETYLENE DERIVATIVES AS STEAROYL COA DESATURASE INHIBITORS

The present invention provides Stearoyl CoA Desaturase (SCD) inhibitors, hi particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by Stearoyl CoA Desaturase 1 (SCD 1) inhibitors. Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by Stearoyl CoA Desaturase (SCD) inhibitors.

4-Amino-5-aryl-6-arylethynylpyrimidines: Structure-activity relationships of non-nucleoside adenosine kinase inhibitors

A series of non-nucleoside adenosine kinase (AK) inhibitors is reported. These inhibitors originated from the modification of 5-(3-bromophenyl)-7-(6-morpholin-4-ylpyridin-3-yl)pyrido[2,3-d]pyrimidin-4-ylamine (ABT-702). The identification of a linker that would approximate the spatial arrangement found between the pyrimidine ring and the aryl group at C(7) in ABT-702 was a key element in this modification. A search of potential linkers led to the discovery of an acetylene moiety as a suitable scaffold. It was hypothesized that the aryl acetylenes, ABT-702, and adenosine bound to the active site of AK (closed form) in a similar manner with respect to the orientation of the heterocyclic base. Although potent acetylene analogs were discovered based on this assumption, an X-ray crystal structure of 5-(4-dimethylaminophenyl)-6-(6-morpholin-4-ylpyridin-3-ylethynyl)pyrimidin-4-ylamine (16a) revealed a binding orientation contrary to adenosine. In addition, this compound bound tightly to a unique open conformation of AK. The structure-activity relationships and unique ligand orientation and protein conformation are discussed.

DOPAMINE D4 RECEPTOR LIGANDS

Described herein are D4 receptor-selective compounds of the formula: STR1 wherein R 1 is selected from H and an acid labile protecting group; and R 2 and R 3 are independently selected from H, radioisotopic halo, loweralkoxy and tri(loweralkyl)tin; and salts, solvates or hydrates thereof.Also described is the use of these compounds as pharmaceuticals to treat indications for which a dopamine D4 receptor antagonist is indicated. Radiolabeled compounds are useful particularly to image localization of D4 receptor in the human brain, and can therefore aid in the diagnosis of schizophrenia and other medical conditions in which the D4 receptor is implicated.